Compugen Ltd. · NASDAQ:CGEN
Compugen — R&D Leaders' Forum Autumn 2004
26 slides from Compugen's conference presentation, October 2004
Slide 1: Improving the Odds: Maximizing the Value of Information at Early Discovery Stages
Improving the Odds: Maximizing the Value of Information at Early Discovery Stages Mor Amitai, Ph.D. President & CEO, Compugen Ltd. R&D Leaders’ Forum Autumn 2004
Slide 2: Agenda
Agenda • Introduction • Genomic Infrastructure • Therapeutic Protein Discovery Engine • Diagnostic Marker Discovery Engine • Summary
Slide 3: Introduction
= Introduction
Slide 4: Probability Of Success (POS)
Probability Of Success (POS) • POS: The chances a given discovery will result in a product • Our goal – To increase the probability of success of drug and diagnostic development by incorporating ideas and methods from mathematics, computer science, and physics into the disciplines of biology, organi
Slide 5: What We Do
What We Do • Build technologies that address POS- critical components in the drug discovery process • Current major technologies: – Genomic infrastructure platforms – Discovery engines: therapeutic proteins and biomarkers
Slide 6: R&D Process
R&D Process Analysis, mathematical modeling, predictions Lab studies, Computational validation, Manual proof
Slide 7: Genomic Infrastructure
> Genomic Infrastructure
Slide 8: The LEADS Process
The LEADS Process • Computational biology platform • Used by, among others: • Unique modeling of biological phenomena
Slide 9: Alternative Splicing
Alternative Splicing Science. May 2003 Genome Res. July 2003 Trends in Genetics. February 2004 Molecular Cell. April 2004
Slide 10: Antisense
Antisense F Enhancing transplant shelf life and effic Pumps for broad-spectrum herbicide resista
Slide 11: RNA Editing
Systematic identification of abundant A-to-| editing sites in the human transcriptome Erez Y Levanon!+, Eli Eisenberg, Rodrigo Yelin'*, Sergey Nemzer'*, Martina Hallegger*, Ronen Shemesh!, Zipora Y Fligelman! Avi Shoshan!, Sarah R Pollock!, Dan Sztybel!, Moshe Olshansky', Gideon Rechavi? & Michael F
Slide 12: Therapeutic Discovery Engine
Therapeutic Discovery Engine
Slide 13: Therapeutic Discovery Engines
Therapeutic Discovery Engines LEADS Engine monitored and improved
Slide 14: Criteria for Selection of Therapeutic Proteins
Criteria for Selection of Therapeutic Proteins • Splice variant related to known drugs • Novelty • Indication that proteins may have unique advantage
Slide 15: Initial Pipeline
Initial Pipeline • CGEN-40 • VEGF-114 • CGEN-G11 • CGEN-B2 • CGEN-M3 • CGEN-P4 • PSA-LM and K-LM Four additional proteins to be added this year
Slide 16: CGEN-40 Candidates
CGEN-40 Candidates • 5 novel secreted forms of CD40 – Both agonists and antagonists – Patents beginning to be granted • Existence verified in the lab • Natural molecules – probably: – Fewer side effects – Less immunogenic • Potential indications: autoimmunity, transplantation, inflammation, cancer
Slide 17: VEGF-114
VEGF-114 • Shortest known variant of VEGF • Patent granted • Licensed to MultiGene Vascular Systems (MGVS) for gene and cell therapy in cardiovascular disease • Further validated by MGVS
Slide 18: CGEN-G11
CGEN-G11 • Hormone • Natural molecule – potentially fewer side effects • Potential indications – Type II Diabetes – Obesity
Slide 19: CGEN-B2
CGEN-B2 • Growth Factor • Natural molecule – potentially fewer side effects • Potential indications in various cancers – Breast, Ovarian, Gastric, Lung, Oral • Potential soluble marker
Slide 20: CGEN-M3
CGEN-M3 • Tyrosine kinase receptor • Proto-oncogene • Soluble receptor • Natural molecule – potentially fewer side effects • Potential indications – Breast, ovarian, lung, pancreatic, colorectal cancers
Slide 21: CGEN-P4
CGEN-P4 • Peptide • Appetite regulator • Natural molecule – potentially fewer side effects • Potential indications – Obesity and eating disorders
Slide 22: Biomarker Discovery Engine
= Biomarker Discovery Engine
Slide 23: Cancer Biomarker Engine
Cancer Biomarker Engine Oligo LEADS Microarray Analysis design Identify candidates over- expressed in cancer Quantitative IP RT-PCR Initially validated novel markers
Slide 24: PSA-LM and K-LM
PSA-LM and K-LM Licensed to DPC for diagnostic products J Biol Chem. 2002 May 17;277(20):18084-90
Slide 25: Engines Summary
Engines Summary • Engines feed our internal pipeline • Rely on integration of mathematical modeling and wet biology • Unique IP stems from accurate modeling • Current engines focus on TP and Dx, and validate capability for additional discovery engines • Promising candidates quickly identified; initi
Slide 26: www.cgen.com
= Wwww.cgen.com